Key Points
- Insider Richard Wright sold 49,298 Celldex shares on Nov. 13 at an average price of $24 for proceeds of $1.183M, trimming his stake by 70.29% to 20,833 shares (worth about $500k).
- Celldex reported a quarterly EPS of ($1.01), missing the ($0.88) estimate and showing deeply negative profitability (ROE -27.61%, net margin -3,446.88%).
- The stock opened at $26 (up ~1.8%), has a $1.73B market cap and a MarketBeat consensus of "Moderate Buy" with a $43.80 target amid mixed analyst ratings and recent price-target revisions.
Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) insider Richard Wright sold 49,298 shares of the stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $24.00, for a total transaction of $1,183,152.00. Following the transaction, the insider owned 20,833 shares of the company's stock, valued at $499,992. This trade represents a 70.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Celldex Therapeutics Stock Up 1.8%
Celldex Therapeutics stock opened at $26.00 on Tuesday. The company's 50-day moving average price is $25.61 and its 200-day moving average price is $22.92. The company has a market cap of $1.73 billion, a PE ratio of -8.64 and a beta of 1.36. Celldex Therapeutics, Inc. has a twelve month low of $14.40 and a twelve month high of $29.05.
Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%. As a group, sell-side analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Celldex Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Aster Capital Management DIFC Ltd purchased a new stake in Celldex Therapeutics in the 3rd quarter valued at about $26,000. Nisa Investment Advisors LLC increased its position in shares of Celldex Therapeutics by 171.7% during the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 881 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Celldex Therapeutics during the third quarter valued at approximately $42,000. Russell Investments Group Ltd. boosted its holdings in shares of Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock valued at $47,000 after purchasing an additional 501 shares during the period. Finally, Quantbot Technologies LP bought a new position in Celldex Therapeutics in the third quarter worth approximately $63,000.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on CLDX. Mizuho started coverage on Celldex Therapeutics in a research report on Tuesday, October 21st. They set an "outperform" rating and a $48.00 target price on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Celldex Therapeutics in a research report on Wednesday, October 8th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $62.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, September 17th. Barclays reduced their price objective on shares of Celldex Therapeutics from $25.00 to $21.00 and set an "underweight" rating on the stock in a research report on Tuesday, November 11th. Finally, Citigroup dropped their target price on Celldex Therapeutics from $56.00 to $48.00 and set a "buy" rating for the company in a research report on Wednesday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $43.80.
Get Our Latest Stock Report on Celldex Therapeutics
Celldex Therapeutics Company Profile
(
Get Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
